Skip to main content
Premium Trial:

Request an Annual Quote

Miragen, Servier Extend microRNA Drug Alliance

Premium

NEW YORK (GenomeWeb) – Miragen Therapeutics this week announced that its research and development collaboration with France's Servier has been extended by two years to October 2016.

The companies first began working together in October 2011 under a three-year deal that gave Servier the rights to three of Miragen's preclinical microRNA inhibitor programs in cardiovascular disease in markets outside the US and Japan. These include ones focused on miR-208 for chronic heart failure, miR-15/195 for treating post-myocardial infarction remodeling, and a yet-to-be disclosed third program.

In exchange, Miragen received $45 million over the term of the arrangement, including upfront payments and milestones. Miragen also stands to receive royalties on product sales.

Financial terms of the extended partnership were not disclosed.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.